Recent Quotes (30 days)

You have no recent quotes
chg | %

Cipher Pharmaceuticals Inc  

(Public, TSE:CPH)   Watch this stock  
Find more results for TSE:DND
13.87
-0.46 (-3.21%)
Apr 17 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 13.84 - 14.20
52 week 7.41 - 19.52
Open 14.01
Vol / Avg. 101,595.00/42,422.00
Mkt cap 359.12M
P/E 17.51
Div/yield     -
EPS 0.79
Shares 25.89M
Beta -0.67
Inst. own     -
Mar 3, 2015
Cipher Pharmaceuticals Inc at Cowen Health Care Conference
Feb 25, 2015
Q4 2014 Cipher Pharmaceuticals Inc Earnings Release
Feb 25, 2015
Q4 2014 Cipher Pharmaceuticals Inc Earnings Call - Webcast
  

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 42.83% 63.96%
Operating margin 53.70% 61.27%
EBITD margin - 67.80%
Return on average assets 19.86% 31.23%
Return on average equity 23.98% 40.69%
Employees 13 -
CDP Score - -

Address

5650 Tomken Rd., Unit 16
MISSISSAUGA, ON L4W 4P1
Canada
+1-905-6025840 (Phone)
+1-905-6020628 (Fax)

Website links

Description

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company focused on dermatology. The Company acquires products that fulfill medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly or through partners. The Company's dermatology products include Sitavig, Absorica, Epuris, Beteflam, Dermadexin, Pruridexin, Ozenoxacin, CF101, ASF-1096 and Nanolipolee-007. The Company's other products include Lipofen, Conzip and Durela.

Officers and directors

Gerald P. McDole Independent Chairman of the Board
Age: 74
Shawn Patrick O'Brien President, Chief Executive Officer
Norman C. Evans Chief Financial Officer, Secretary
Age: 60
Joan Chypyha Vice President - Marketing and Sales
Linda Melanie Angaritis Vice President - Global Regulatory Compliance and Quality
Lynne Bulger Vice President - Medical and Clinical Affairs
Peter Weiler Vice President - Business Development
Stefan Aigner M.D. Independent Director
William D. Claypool M.D. Independent Director
Age: 61
John D. Mull M.D. Independent Director